# Compare NAD+ and MOTS-c — AgeDefy Peptide

> A side-by-side comparison of two Longevity & Cellular Health research molecules — NAD+ and MOTS-c — across molecule class, evidence base, administration studied, regulatory status, and key cautions.

Where NAD+ and MOTS-c converge on cellular aging, where they diverge in evidence strength, and how far the research behind each one actually reaches.

## The short version

This page lines up [NAD+](/nad) and [MOTS-c](/mots-c) on the dimensions that matter most when reading longevity research: what kind of molecule each one is, where it has been studied most, how strong that evidence is, how it was given in studies, its regulatory standing, and its single biggest open question. The headline is straightforward. Both molecules connect to mitochondrial function and cellular energy as central themes. NAD+ has a deep human clinical trial record for blood-level pharmacodynamics, while translation to hard clinical outcomes remains contested; MOTS-c has a mechanistically compelling animal record but no completed human interventional trials at all. Neither is an approved medicine, and neither is presented here with a human dose.

## The comparison matrix

| Dimension | NAD+ | MOTS-c |
| --- | --- | --- |
| Molecule class | Dinucleotide coenzyme / dietary supplement and compounded injectable | Mitochondrial-derived peptide (16 aa), encoded in MT-RNR1 |
| Most-studied in | Cellular energy metabolism, DNA repair, aging, metabolic health | Skeletal muscle glucose handling, physical performance, AMPK signaling |
| Evidence base (model) | Human clinical trials (NMN, NR) + rodent mechanistic; 2025 review: blood NAD+ elevation well established, clinical outcomes limited [1][2][5] | Primarily mice and cell assays; one human observational cohort [9][11] |
| Administration studied | Oral (NMN, NR supplements); IV infusion (compounded); oral in human RCTs [2][3][5] | Subcutaneous or intraperitoneal in mice; no human interventional route established [8][11] |
| Regulatory / WADA status | Not an approved drug; precursors sold as supplements; NMN supplement status contested; WADA: not prohibited | Not approved; research chemical only; WADA-prohibited under metabolic modulators |
| Key caution | Blood NAD+ elevation is real; translation to clinical longevity benefit is unproven [1] | No human efficacy trials; all animal performance and metabolic data [10] |

## Molecule class

The two molecules could hardly differ more structurally. NAD+ is a dinucleotide — a small-molecule coenzyme made from nicotinamide and adenosine nucleotides — that functions as a recyclable electron carrier in energy metabolism and a consumed substrate for sirtuin and PARP signaling. It is endogenous, abundant in every cell, and its precursors are widely sold as dietary supplements [4]. MOTS-c is a true peptide — sixteen amino acids — encoded inside the mitochondrial genome itself, a class of molecules discovered only within the past two decades [10]. Their structural contrast maps onto a difference in regulatory context: NAD+ precursors occupy supplement and compounded-IV markets, while MOTS-c is a research chemical with no approved formulation.

## Most-studied in

Each molecule has a home territory in the literature. NAD+ research spans cellular energy metabolism, the DNA-damage response (via PARP), gene regulation (via sirtuins), age-related metabolic decline, and now heart failure [4][7]. MOTS-c research centers on skeletal muscle: glucose uptake, insulin sensitivity, and age-related physical decline, with a strong thread linking it to exercise biology as both an exercise-induced signal and a potential exercise-mimetic [11].

## Evidence base (model)

This is where the two genuinely separate. NAD+ has the richer human trial record: multicenter RCTs have documented blood NAD+ elevation with NMN and NR, one study in prediabetic women showed improved muscle insulin sensitivity [3], and the cardiac HFpEF data extend the story to human myocardium [7]. The 2025 *Nature Metabolism* review represents the most current authoritative synthesis: it confirms blood-level pharmacodynamics are real but calls clinical-endpoint translation limited and tissue-specific data sparse [1]. MOTS-c's strongest human data are one observational cohort study in hemodialysis patients associating circulating MOTS-c with mortality risk [9] — no interventional human trial has been completed [10].

## Administration studied

Routes reflect the evidence stage. NAD+ precursors have been studied in formal oral RCTs — multicenter, double-blind, placebo-controlled — in healthy middle-aged adults and prediabetic women [2][3][5]. IV NAD+ infusions are used in compounded-wellness contexts, though controlled evidence for this route is minimal and one formulation was recalled for endotoxin contamination [1]. MOTS-c has been studied subcutaneously and intraperitoneally in mice [8][11]; no validated human route, dose, or formulation exists.

## Regulatory / WADA status

NAD+ and NR are not WADA-prohibited, and their precursors are generally sold as dietary supplements, though the FDA has contested the supplement status of NMN on the grounds that it was investigated as a drug. Compounded injectable NAD+ is not FDA-approved and carries the contamination risks inherent to compounded products [1]. MOTS-c is not approved by the FDA or any major regulator for any use, is sold only for laboratory research, and is treated as a prohibited substance by WADA under hormone and metabolic-modulator categories — athletes in governed sport face sanctions for use.

## Key caution

Each molecule carries a defining caveat. For NAD+ it is that blood-level pharmacodynamics are well established, but the leap to longevity or disease-prevention endpoints in humans has not been made — the 2025 review makes this point directly, and the cardiac HFpEF finding, while promising, is one pre-clinical-to-human translation step, not a population-level outcome [1][7]. For MOTS-c it is simpler and starker: every efficacy claim about exogenous MOTS-c improving metabolism, physical performance, or aging in humans comes from animal studies, and the one human dataset is observational [9][10]. Reading them together, the lesson the cellular aging field has to offer is consistent: compelling mechanisms and real signals, in a literature that still owes the reader controlled human trials.

---

A calm literature desk for cellular aging research — citations and context, not prescriptions and not products.